OIPE JUL 2 3 2004 PATENT & TRADEMARK OFFICE TC73

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/678,160
Filing Date	10/06/2003
First Named Inventor	Sprecher
Group Art Unit	~~1615~~ 1655
Examiner Name	BY K. C. SRINIVAS RAO
Attorney Docket Number	26465

Sheet 1 Of 3

U.S. PATENT DOCUMENTS

Examiners Initials	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		4,139,619		Chidsey, III	02-13-1979	
		5,994,319		Hoke, Jr.	11-30-1999	
		5,226,907		Tankovitch	07-13-1993	
		6,251,676		Shioda et al	06-26-2001	
		5,659,055		Franson et al	08-19-1997	
		6,051,381		Kornacker	04-18-2000	
		4,746,674		Pierpaoli	05-24-1988	
		5,425,728		Tankovitch	06-20-1995	
		5,177,061		Pickart	01-05-1993	
		4,832,946		Green	05-23-1989	
		5,068,315		Buultjens et al	11-26-1991	
		5,358,714		Green	10-25-1994	

FOREIGN PATENT DOCUMENTS

Examiners Initials	Cite No.[1]	Foreign Patent Documents Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	12/19/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IPE JC73 JUL 23 2004 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/678,160
Filing Date	10/06/2003
First Named Inventor	Sprecher
Group Art Unit	~~1615~~ 1655
Examiner Name	D. R. SRIVASTAVA
Attorney Docket Number	26465

Sheet 2 Of 3

Examiner Initials	Cite No.[1]	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		Takaishi et al, "Regulation of cell-cell adhesion by rac and rho small G proteins in MDCK cells", *J Cell Biol.* 1997 Nov 17;139(4):1047-59.	
		Cos et al, "Melatonin modulates growth factor activity in MCF-7 human breast cancer cells", *J Pineal Res.* 1994 Aug;17(1):25-32.	
		Low et al, "Chemical Characterization of Thymosin β_4", *J Biological Chem.*, 257(2):1000-1006, 1982	
		Radice et, "Precocious mammary gland development in P-cadherin-deficient mice", *J Cell Biol.* 1997 Nov 17;139(4):1025-32.	
		Riehl et al, "Cadherin function is required for axon outgrowth in retinal ganglion cells in vivo", *Neuron.* 1996 Nov;17(5):837-48.	
		Bazzano et al, "Effect of retinoids on follicular cells", *J Invest Dermatol.* 1993 Jul;101(1 Suppl):138S-142S.	
		Jiang et al, "Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant", *J Invest Dermatol.* 1995 Apr;104(4):523-5.	
		Lewis et al, "Cadherin function is required for human keratinocytes to assemble desmosomes and stratify in response to calcium", *J Invest Dermatol.* 1994 Jun;102(6):870-7.	
		Liuzzi et al, "A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo", *Nature.* 1994 Dec 15;372(6507):695-8.	
		Fields et al, "A novel genetic system to detect protein-protein interactions", *Nature.* 1989 Jul 20;340(6230):245-6.	
		Yan et al, "Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype", *Cancer Res.* 1995 Aug 15;55(16):3569-75.	
		Molis et al, "Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells", *Mol Endocrinol.* 1994 Dec;8(12):1681-90.	
		Zappacosta, A., "Reversal of baldness in patient receiving minoxidil for hypertension", *N Engl J Med.* 1980 Dec 18;303(25):1480-1.	
		Chen et al, "Progesterone regulates beta-catenin mRNA levels in human endometrial stromal cells in vitro", *Endocrine.* 1998 Dec;9(3):263-7.	
		Bolz et al, "Mutation of CDH23, encoding a new member of the cadherin gene family, causes Usher syndrome type 1D", *Nat Genet.* 2001 Jan;27(1):108-12.	
		Alexeev et al, "Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide", *Nat Biotechnol.* 2000 Jan;18(1):43-7.	
		Yagi et al, "Cadherin superfamily genes: functions, genomic organization, and neurologic diversity", *Genes Dev.* 2000 May 15;14(10):1169-80.	
Examiner Signature		Date Considered	12/21/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]. Unique citation designation number. [2]. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC73 JUL 23 2004 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/678,160
Filing Date	10/06/2003
First Named Inventor	Sprecher
Group Art Unit	~~1615~~ 1655
Examiner Name	K S Rump
Attorney Docket Number	26465

Sheet 3 Of 3

Examiner Initials	Cite No.[1]	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		Plum et al, "Connexin31-deficiency in mice causes transient placental dysmorphogenesis but does not impair hearing and skin differentiation", *Dev Biol.* 2001 Mar 15;231(2):334-47.	
		Ahmed et al, "Mutations of the protocadherin gene PCDH15 cause Usher syndrome type 1F", *Am J Hum Genet.* 2001 Jul;69(1):25-34.	
		Raison-Peyron et al, "A syndrome combining severe hypotrichosis and macular dystrophy: absence of mutations in TIMP genes", *Br J Dermatol.* 2000 Oct;143(4):902-4	
		Da Cruz et al, "An Australian family with macular dystrophy linked to autosomal recessive alopecia universalis", *Br J Ophthalmol.* 2001 Feb;85(2):238	
		Monks et al, "N-cadherin is regulated by gonadal steroids in the adult hippocampus", *Proc Natl Acad Sci U S A.* 2001 Jan 30;98(3):1312-6	
		Heulsken et al, "beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin", *Cell.* 2001 May 18;105(4):533-45.	
		Gat et al, "De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin", *Cell.* 1998 Nov 25;95(5):605-14.	

Examiner Signature		Date Considered	12/21/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]. Unique citation designation number. [2]. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.